ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits. Its product pipeline includes VAL101, VAL201, VAL401 and Nav3. VAL201 is an anti-cancer therapeutic drug, which is in clinical trials for the treatment of prostate cancer and other indications of hormone induced unregulated growth including endometriosis. VAL401 is the reformulation of a generic drug for treatment of a chronic non-oncology disease in an oral capsule. VAL101 is a therapeutic based on its Gene Inactivation by chromatin engineering (GeneICE) platform. NAV3 Cancer Screening Test enables the detection of cancer cells in tissue samples. It operates through divisional companies, including ValiPharma, ValiFinn and ValiSeek.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: LON:VAL
- CUSIP: N/A
- Web: www.valirx.com
Capitalization:- Market Cap: £2.82 million
- Outstanding Shares: 130,962,000
Average Prices:- 50 Day Moving Avg: GBX 2.09
- 200 Day Moving Avg: GBX 3.01
- 52 Week Range: GBX 1.87 - GBX 11.49
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: GBX 0.03 per share
- Price / Book: 0.72
Profitability:- EBIDTA: ($4,070,000.00)
- Return on Equity: -200.19%
- Return on Assets: -122.10%
Misc:- Average Volume: 739,169 shs.
Frequently Asked Questions for ValiRx Plc (LON:VAL)
What is ValiRx Plc's stock symbol?
ValiRx Plc trades on the London Stock Exchange (LON) under the ticker symbol "VAL."
When will ValiRx Plc make its next earnings announcement?
Where is ValiRx Plc's stock going? Where will ValiRx Plc's stock price be in 2017?
1 brokerages have issued 1 year price targets for ValiRx Plc's shares. Their forecasts range from GBX 6.50 to GBX 6.50. On average, they expect ValiRx Plc's share price to reach GBX 6.50 in the next twelve months. View Analyst Ratings for ValiRx Plc.
Who are some of ValiRx Plc's key competitors?
Some companies that are related to ValiRx Plc include Ariad Pharmaceuticals (ARIA), Auspex Pharmaceuticals (ASPX), Biotie Therapies Corp (BITI), Cynapsus Therapeutics (CYNA), Dyax Corp. (DYAX), Kythera Biopharmaceuticals (KYTH), Medivation (MDVN), MEI Pharma (MSHL), NPS Pharmaceuticals (NPSP), Ocata Therapeutics (OCAT), Raptor Pharmaceutical Corp (RPTP), Receptos (RCPT), Relypsa (RLYP), SalvaRx Group Plc (3LEG), Sarepta Therapeutics (AVII), Tobira Therapeutics (TBRA) and ZS Pharma (ZSPH).
Who are ValiRx Plc's key executives?
ValiRx Plc's management team includes the folowing people:
- Satu Vainikka, Chief Executive Officer, Director
- Gerald Desler, Chief Financial Officer, Director
- George Morris, Chief Operating Officer, Director
- Kevin John Alexander, Secretary, Non-Executive Director
- Oliver de Giorgio-Miller, Non-Executive Chairman of the Board
- Seppo Olavi Makinen, Non-Executive Director
How do I buy ValiRx Plc stock?
Shares of ValiRx Plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is ValiRx Plc's stock price today?
One share of ValiRx Plc stock can currently be purchased for approximately GBX 2.15.
MarketBeat Community Rating for ValiRx Plc (LON VAL)MarketBeat's community ratings are surveys of what our community members think about ValiRx Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ValiRx Plc (LON:VAL) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating |
| Consensus Rating: | Hold (Score: 2.00) |
| Consensus Price Target: | GBX 6.50 |
Analysts' Ratings History for ValiRx Plc (LON:VAL)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 6/16/2017 | Beaufort Securities | Reiterated Rating | Speculative Buy | GBX 6.50 |  |
| 12/8/2016 | Northland Securities | Reiterated Rating | Corporate | | |
| 11/5/2015 | Northland Capital Partners | Reiterated Rating | corporate | | |
(Data available from 7/22/2015 forward)
Earnings History for ValiRx Plc (LON:VAL)Earnings History by Quarter for ValiRx Plc (LON VAL)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 9/25/2017 | | | | | | | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ValiRx Plc (LON:VAL)Current Year EPS Consensus Estimate: $0.00 EPS
Dividend History for ValiRx Plc (LON:VAL)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for ValiRx Plc (LON:VAL)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for ValiRx Plc (LON:VAL)
Latest Headlines for ValiRx Plc (LON:VAL)
| Source: |
|
ValiRx Plc (VAL) Chart for Saturday, July, 22, 2017
